ERBB2 and neoplasm: Next, we assessed the expression of the 56 genes/signatures in paired tumor samples from 36 patients with HER2+/HER2-E disease recruited in the LPT109096 phase II clinical trial23, where patients were treated for 2 weeks with either lapatinib, trastuzumab or the combination.